Goldman Sachs raised the firm's price target on Amneal Pharmaceuticals to $17 from $15 and keeps a Buy rating on the shares. Amneal Pharmaceuticals shares pulled back slightly after Q4 EPS due to softer GRx performance and FY26 topline guidance from the distribution segment, though the strong FY26 EBITDA outlook supports a long-term growth thesis that remains intact, the analyst tells investors in a research note.
